Table 1.

Representatives of pan-FGFR inhibitors that target FGFRs.

Inhibitor	Targets	Disease Type	Reference
AZD4547	FGFR1–3	ER+ breast cancer	[12]
Derazantinib (ARQ-087)	FGFR1–4	Advanced intrahepatic cholangiocarcinoma with FGFR2 gene aberrations	[13]
Erdafitinib (JNJ42756493)	FGFR1–4	Locally advanced or metastatic bladder cancer, etc.	[14]
Futibatinib (TAS-120)	FGFR1–4	Metastatic breast cancer with FGFR2 amplification	[15]
Infigratinib (BGJ398)	FGFR1–3	Advanced or metastatic cholangiocarcinoma	[16]
LY2874455	FGFR1–4	Advanced cancer	[17]
Pemigatinib (INCB054828)	FGFR1–3	Unresectable or metastatic cholangiocarcinoma	[18]
Rogaratinib (BAY1163877)	FGFR1–3	Squamous non-small cell lung cancer	[19]
Zoligratinib (Debio-1347)	FGFR1–3	Advanced solid tumors	[20]